Differences in wage earnings between psoriasis patients on biologics versus those on oral therapies: a population-based study in the United States

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology (Basel, Switzerland). 2012;225(2):121–126.
   PubMed Web of Science ®Google Scholar
• Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther. 2010;23(2):114–118.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Symmons D, Peters MJL, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–216.
   PubMed Web of Science ®Google Scholar
• Coto-Segura P, Eiris-Salvado N, Gonzalez-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169(4):783–793.
   PubMed Web of Science ®Google Scholar
• Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–728.
   PubMed Web of Science ®Google Scholar
• Bojke L, Spackman E, Hinde S, et al. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatology (Oxford, England). 2012;51(2):210–215.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Pike J, et al. Satisfaction with current psoriasis treatment: misalignment between physician and patient perceptions. Dermatol Online J. 2016;22(7):1–11.
   Google Scholar
• Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24–28.
   PubMed Web of Science ®Google Scholar
• Ayala F, Sampogna F, Romano GV, et al. The impact of psoriasis on work-related problems: a multicenter cross-sectional survey. J Eur Acad Dermatol Venereol. 2014;28(12):1623–1632.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS One. 2012;7(12):e52935.
   PubMed Web of Science ®Google Scholar
• Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012–1019.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661–669.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658.
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics USDoL, Occupational Outlook Handbook, Major Economic Indicators. [visited 2019 Jun 6]. Available from: https://www.bls.gov/bls/newsrels.htm
   Google Scholar
• Medical Expenditure Panel Survey (MEPS). Content last reviewed August 2018. Agency for Healthcare Research and Quality, Rockville, MD. Available from: https://www.ahrq.gov/data/meps.html
   Google Scholar
• Banthin JS, Selden TM. Income measurement in the medical expenditure panel survey. Agency for healthcare research and quality working paper No. 06005; July 2006. Available from: http://gold.ahrq.gov
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Feldman SR, Zhao Y, Gilloteau I, et al. Higher psoriasis skin clearance is associated with lower annual indirect costs in the united states: a post hoc analysis from the CLEAR Study. JMCP. 2018;24(7):617–622.
   PubMed Web of Science ®Google Scholar
• Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. Arch Dermatol Res. 2019;311(6):453.
   PubMed Web of Science ®Google Scholar
• Tillett W, Shaddick G, Jobling A, et al. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology (Oxford, England). 2017;56(4):603–612.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66(2):e67–e76.
   PubMedGoogle Scholar
• Zhang W, Islam N, Ma C, et al. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015;33(4):327–340.
   PubMed Web of Science ®Google Scholar
• Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology (Basel, Switzerland). 2006;213(2):102–110.
   PubMed Web of Science ®Google Scholar